Search by Drug Name or NDC

    NDC 17772-0131-90 QELBREE 100 mg/1 Details

    QELBREE 100 mg/1

    QELBREE is a ORAL CAPSULE, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Supernus Pharmaceuticals, Inc. The primary component is VILOXAZINE HYDROCHLORIDE.

    Product Information

    NDC 17772-0131
    Product ID 17772-131_0cf4dfd5-09e2-4829-e063-6294a90afbfc
    Associated GPIs 61354080207020
    GCN Sequence Number 082132
    GCN Sequence Number Description viloxazine HCl CAP ER 24H 100 MG ORAL
    HIC3 H7Y
    HIC3 Description TX FOR ATTENTION DEFICIT-HYPERACT.(ADHD), NRI-TYPE
    GCN 49447
    HICL Sequence Number 007345
    HICL Sequence Number Description VILOXAZINE HCL
    Brand/Generic Brand
    Proprietary Name QELBREE
    Proprietary Name Suffix n/a
    Non-Proprietary Name viloxazine hydrochloride
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form CAPSULE, EXTENDED RELEASE
    Route ORAL
    Active Ingredient Strength 100
    Active Ingredient Units mg/1
    Substance Name VILOXAZINE HYDROCHLORIDE
    Labeler Name Supernus Pharmaceuticals, Inc
    Pharmaceutical Class Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA211964
    Listing Certified Through 2024-12-31

    Package

    NDC 17772-0131-90 (17772013190)

    NDC Package Code 17772-131-90
    Billing NDC 17772013190
    Package 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-90)
    Marketing Start Date 2021-04-02
    NDC Exclude Flag N
    Pricing Information N/A